AU2019276359B2 - Quinoline derivatives as inhibitors of Axl/Mer RTK and CSF1R - Google Patents
Quinoline derivatives as inhibitors of Axl/Mer RTK and CSF1R Download PDFInfo
- Publication number
- AU2019276359B2 AU2019276359B2 AU2019276359A AU2019276359A AU2019276359B2 AU 2019276359 B2 AU2019276359 B2 AU 2019276359B2 AU 2019276359 A AU2019276359 A AU 2019276359A AU 2019276359 A AU2019276359 A AU 2019276359A AU 2019276359 B2 AU2019276359 B2 AU 2019276359B2
- Authority
- AU
- Australia
- Prior art keywords
- cancer
- mmol
- mixture
- lcms
- give
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Diabetes (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Psychology (AREA)
- Ophthalmology & Optometry (AREA)
- Cardiology (AREA)
- Child & Adolescent Psychology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Pulmonology (AREA)
- Urology & Nephrology (AREA)
- Transplantation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862677902P | 2018-05-30 | 2018-05-30 | |
| US62/677,902 | 2018-05-30 | ||
| PCT/EP2019/064214 WO2019229251A1 (en) | 2018-05-30 | 2019-05-31 | Quinoline derivatives as inhibitors of axl/mer rtk and csf1r |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2019276359A1 AU2019276359A1 (en) | 2020-10-29 |
| AU2019276359B2 true AU2019276359B2 (en) | 2024-10-03 |
Family
ID=66770463
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2019276359A Active AU2019276359B2 (en) | 2018-05-30 | 2019-05-31 | Quinoline derivatives as inhibitors of Axl/Mer RTK and CSF1R |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US12162858B2 (enExample) |
| EP (1) | EP3774776A1 (enExample) |
| JP (2) | JP7390313B2 (enExample) |
| CN (1) | CN112313216B (enExample) |
| AU (1) | AU2019276359B2 (enExample) |
| BR (1) | BR112020021370A2 (enExample) |
| CA (1) | CA3097694A1 (enExample) |
| IL (1) | IL278960B2 (enExample) |
| MX (1) | MX2020011636A (enExample) |
| PH (1) | PH12020551806A1 (enExample) |
| SG (1) | SG11202009971QA (enExample) |
| WO (1) | WO2019229251A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201905721D0 (en) | 2019-04-24 | 2019-06-05 | Univ Dundee | Compounds |
| IL315474A (en) * | 2022-03-30 | 2024-11-01 | Qurient Co Ltd | New forms of n-(5-((6,7-dimethoxyquinolin-4-yl)oxy)pyridin-2-yl)-1-propyl-4-(2,2,2-trifluoroethoxy)-1h-pyrazole-3 -carboxamide hydrochloride |
| CN117637185B (zh) * | 2024-01-25 | 2024-04-23 | 首都医科大学宣武医院 | 一种基于影像的颅咽管瘤治疗辅助决策方法、系统及设备 |
| CN118593494B (zh) * | 2024-08-08 | 2024-11-01 | 四川大学华西医院 | Nampt抑制剂在制备预防和/或治疗色素沉着绒毛结节性滑膜炎的药物中的用途 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6143764A (en) | 1995-11-07 | 2000-11-07 | Kirin Beer Kabushiki Kaisha | Quinoline and quinazoline derivatives inhibiting platelet-derived growth factor receptor autophosphorylation and pharmaceutical compositions containing the same |
| EP2311809A1 (en) | 2009-10-16 | 2011-04-20 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Quinolinyloxyphenylsulfonamides |
| EP2423208A1 (en) | 2010-08-28 | 2012-02-29 | Lead Discovery Center GmbH | Pharmaceutically active compounds as Axl inhibitors |
| ES2590778T3 (es) | 2011-02-28 | 2016-11-23 | Calitor Sciences, Llc | Compuestos de quinolina sustituida |
| ES2749726T3 (es) | 2014-12-25 | 2020-03-23 | Ono Pharmaceutical Co | Derivado de quinolina |
| EP3286177B1 (en) * | 2015-04-14 | 2020-05-06 | Qurient Co. Ltd. | Quinoline derivatives as tam rtk inhibitors |
| WO2019231942A1 (en) | 2018-06-01 | 2019-12-05 | Rigel Pharmaceuticals, Inc. | Quinoline derivatives useful as tyrosine kinase inhibitors |
-
2019
- 2019-05-31 AU AU2019276359A patent/AU2019276359B2/en active Active
- 2019-05-31 IL IL278960A patent/IL278960B2/en unknown
- 2019-05-31 US US17/047,961 patent/US12162858B2/en active Active
- 2019-05-31 SG SG11202009971QA patent/SG11202009971QA/en unknown
- 2019-05-31 JP JP2020565928A patent/JP7390313B2/ja active Active
- 2019-05-31 BR BR112020021370-5A patent/BR112020021370A2/pt unknown
- 2019-05-31 WO PCT/EP2019/064214 patent/WO2019229251A1/en not_active Ceased
- 2019-05-31 CN CN201980036560.3A patent/CN112313216B/zh active Active
- 2019-05-31 MX MX2020011636A patent/MX2020011636A/es unknown
- 2019-05-31 CA CA3097694A patent/CA3097694A1/en active Pending
- 2019-05-31 EP EP19728645.3A patent/EP3774776A1/en active Pending
-
2020
- 2020-10-29 PH PH12020551806A patent/PH12020551806A1/en unknown
-
2023
- 2023-10-06 JP JP2023174642A patent/JP2023168629A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| PH12020551806A1 (en) | 2021-05-17 |
| US20210163448A1 (en) | 2021-06-03 |
| JP2023168629A (ja) | 2023-11-24 |
| CN112313216A (zh) | 2021-02-02 |
| US12162858B2 (en) | 2024-12-10 |
| KR20210020882A (ko) | 2021-02-24 |
| IL278960B2 (en) | 2024-08-01 |
| IL278960A (en) | 2021-01-31 |
| SG11202009971QA (en) | 2020-11-27 |
| BR112020021370A2 (pt) | 2021-01-19 |
| CN112313216B (zh) | 2025-03-14 |
| AU2019276359A1 (en) | 2020-10-29 |
| NZ768747A (en) | 2025-06-27 |
| MX2020011636A (es) | 2020-12-07 |
| IL278960B1 (en) | 2024-04-01 |
| JP2021525270A (ja) | 2021-09-24 |
| CA3097694A1 (en) | 2019-12-05 |
| JP7390313B2 (ja) | 2023-12-01 |
| WO2019229251A1 (en) | 2019-12-05 |
| EP3774776A1 (en) | 2021-02-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2018311198B2 (en) | Selective inhibitors of NLRP3 inflammasome | |
| EP3468960B1 (en) | Chemical compounds as atf4 pathway inhibitors | |
| AU2019276359B2 (en) | Quinoline derivatives as inhibitors of Axl/Mer RTK and CSF1R | |
| CA2481482C (en) | Tropane derivatives as ccr5 modulators | |
| EP3286177B1 (en) | Quinoline derivatives as tam rtk inhibitors | |
| JP2020111593A (ja) | Ｊａｋキナーゼ阻害剤としてのナフチリジン化合物 | |
| AU2022273631B2 (en) | Lpa receptor antagonists and uses thereof | |
| WO2019158019A1 (zh) | 嘧啶并环化合物及其制备方法和应用 | |
| AU2020413997A1 (en) | Pyridazinyl-thiazolecarboxamide compound | |
| AU2022273702B2 (en) | Lpa receptor antagonists and uses thereof | |
| CA3105942A1 (en) | Chemical compounds | |
| AU2018266911C1 (en) | Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof | |
| WO2020031107A1 (en) | Chemical compounds | |
| KR20210049895A (ko) | 고 활성 sting 단백질 작용제 화합물 | |
| WO2016020836A1 (en) | Quinolone derivatives as antibacterials | |
| CN105814043A (zh) | 用作tnf活性调节剂的三唑并吡啶衍生物 | |
| AU2021276206B2 (en) | Compound used as RET kinase inhibitor and application thereof | |
| JP2020522553A (ja) | Ａｔｆ４経路阻害剤としての化合物 | |
| CA2999379A1 (en) | 2-oxo-1,2-dihydropyridine-3,5-dicarboxamide compounds as bromodomain inhibitors | |
| AU2020385527A1 (en) | Compound used as EGFR kinase inhibitor and use thereof | |
| AU2018320416B2 (en) | Pyridylpyridone compounds | |
| KR20250073137A (ko) | Egfr 억제제 및 그의 용도 | |
| RU2812631C2 (ru) | Производные хинолина в качестве ингибиторов рецепторной тирозинкиназы axl/mer и csf1r | |
| KR102901476B1 (ko) | Axl/mer rtk 및 csf1r의 억제제로서의 퀴놀린 유도체 | |
| WO2024052692A1 (en) | Novel compounds as ck2 inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGA | Letters patent sealed or granted (standard patent) |